Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus

被引：13

作者：

Marucco, D. Aguilar ^{[1
]}

Veronese, L. ^{[1
]}

de Requena, D. Gonzalez ^{[1
]}

Bonora, S. ^{[1
]}

Calcagno, A. ^{[1
]}

Cavecchia, I. ^{[1
]}

Sinicco, A. ^{[1
]}

De Rosa, F. G. ^{[1
]}

Cariti, G. ^{[1
]}

Di Perri, G. ^{[1
]}

机构：

[1] Univ Turin, Amedeo Savoia Hosp, Dept Infect Dis, Turin, Italy

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2007年 / 59卷 / 03期

关键词：

anti-HIV activity; interferons; anti-HCV therapy;

D O I：

10.1093/jac/dkl497

中图分类号：

R51 [传染病];

学科分类号：

100401 [流行病与卫生统计学];

摘要：

Objectives: To evaluate the early anti-HIV activity of pegylated interferon (PEG-IFN) alfa-2a and ribavirin in HIV/hepatitis C virus (HCV) co-infected patients not receiving antiretroviral therapy. Patients and methods: In 19 patients with baseline plasma HIV load (HIV-RNA) >1000 copies/mL treated with PEG-IFN alfa-2a and ribavirin, HIV-RNA and T-cell subsets were measured at baseline and 2, 4 and 12 weeks after initiation of anti-HCV therapy. Results: We observed a significant HIV-RNA decrease (>1 log(10) copies/mL) through week 12 of anti-HCV treatment. The magnitude of HIV-RNA decline was associated with baseline HIV-RNA, CD4 count and PEG-IFN weight-adjusted dose. Conclusions: A significant early anti-HIV activity of PEG-IFN alfa-2a was observed. Such an effect warrants further clinical evaluation in the management of co-infected patients.

引用

页码：565 / 568

页数：4

共 13 条

[1]

Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients [J].

Alberti, A ;

Clumeck, N ;

Collins, S ;

Gerlich, W ;

Lundgren, J ;

Palù, G ;

Reiss, P ;

Thiebaut, R ;

Weiland, O ;

Yazdanpanah, Y ;

Zeuzem, S .

JOURNAL OF HEPATOLOGY, 2005, 42 (05) :615-624

[2]

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial [J].

Carrat, F ;

Bani-Sadr, F ;

Pol, S ;

Rosenthal, E ;

Lunel-Fabiani, F ;

Benzekri, A ;

Morand, P ;

Goujard, C ;

Pialoux, G ;

Piroth, L ;

Salmon-Céron, D ;

Degott, C ;

Cacoub, P ;

Perronne, C .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23) :2839-2848

[3]

Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons [J].

Chung, RT ;

Andersen, J ;

Volberding, P ;

Robbins, GK ;

Liu, T ;

Sherman, KE ;

Peters, MG ;

Koziel, MJ ;

Bhan, AK ;

Alston, B ;

Colquhoun, D ;

Nevin, T ;

Harb, G ;

van der Horst, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :451-459

[4]

GATELL JM, 1991, LANCET, V338, P6

[5]

RESTRICTION OF HIV REPLICATION IN INFECTED T-CELLS AND MONOCYTES BY INTERFERON-ALPHA [J].

GENDELMAN, HE ;

BACA, L ;

TURPIN, JA ;

KALTER, DC ;

HANSEN, BD ;

ORENSTEIN, JM ;

FRIEDMAN, RM ;

MELTZER, MS .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1990, 6 (08) :1045-1049

[6]

Low-dose IFN-α monotherapy in treatment-naive individuals with HIV-1 infection:: Evidence of potent suppression of viral replication [J].

Hatzakis, A ;

Gargalianos, P ;

Kiosses, V ;

Lazanas, M ;

Sypsa, V ;

Anastassopoulou, C ;

Vigklis, V ;

Sambatakou, H ;

Botsi, C ;

Paraskevis, D ;

Stalgis, C .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (10) :861-869

[7]

Hatzakis A, 2000, AIDS, V14, pS18

[8]

A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients [J].

McCallister, S ;

Valdez, H ;

Curry, K ;

MacGregor, T ;

Borin, M ;

Freimuth, W ;

Wang, YY ;

Mayers, DL .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 35 (04) :376-382

[9]

REYNES J, 2000, 7 C RETR OPP INF SAN, P145

[10]

SCHUGT I, 2003, 10 C RETR OPP INF, P78

← 1 2 →